These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35722385)

  • 1. The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment.
    Gan W; Chen X; Wu Z; Zhu X; Liu J; Wang T; Gao Z
    Ann Transl Med; 2022 May; 10(10):536. PubMed ID: 35722385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].
    Pan JL; Luo H; Zhang XX; Han YF; Chen HY; Zeng Z; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):16-21. PubMed ID: 38320786
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.
    Yi S; Ren G; Zhu Y; Cong Q
    Virol J; 2024 Jan; 21(1):22. PubMed ID: 38243304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA.
    Liu YY; Liang XS
    World J Hepatol; 2018 Sep; 10(9):603-611. PubMed ID: 30310538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy.
    Pan J; Xu J; Luo H; Tan N; Kang Q; Chen H; Cheng R; Han Y; Yang Y; Xu X
    Int J Infect Dis; 2021 Apr; 105():418-423. PubMed ID: 33676002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The relationship between serum HBV pgRNA and antigen status in patients with chronic hepatitis B after long-term nucleotide analogues treatment].
    Rao X; Shi HH; Wu ZP; Li XP; Liu XY; Zhang LL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):766-770. PubMed ID: 34517458
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B.
    Laras A; Papatheodoridi M; Panopoulou E; Papatheodoridis GV; Hadziyannis SJ; Hadziyannis E
    Virol J; 2022 Jan; 19(1):22. PubMed ID: 35093105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
    Zhao Q; Liu K; Zhu X; Yan L; Ding Y; Xu Y; Lou S; Zhao G; Xie Q; Gao Y; Bao S; Wang H
    Antiviral Res; 2020 Dec; 184():104953. PubMed ID: 33065138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiles of HBcrAg and pgRNA in Pregnant Women With Chronic HBV Under Different Disease Phases and Antiviral Prophylaxis.
    Wang CR; Liu XQ; Shen W; Zhong GC; Li H; Tang Q; Liu YX; Hu P
    Open Forum Infect Dis; 2024 May; 11(5):ofae241. PubMed ID: 38756766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes.
    Lin N; Ye A; Lin J; Liu C; Huang J; Fu Y; Wu S; Xu S; Wang L; Ou Q
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
    Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
    World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.